Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MRD-positive”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04475731
What this trial is testing

Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

Who this might be right for
Philadelphia-Positive ALLAcute Lymphoblastic Leukemia, in Relapse
Gruppo Italiano Malattie EMatologiche dell'Adulto 67
Early research (Phase 1)Looking for participantsNCT07280494
What this trial is testing

To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT

Who this might be right for
CD7+ T-ALL/LBL
Peking University People's Hospital 18
Not applicableUnknownNCT03971305
What this trial is testing

A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL

Who this might be right for
MRDMDDLymphoma, Nonhodgkin+2 more
Sun Yat-sen University 300
Not applicableStudy completedNCT05440409
What this trial is testing

CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL

Who this might be right for
Leukemia, Acute LymphoblasticLymphoblastic Leukemia, Acute, Childhood
National Cancer Institute (NCI) 57
Testing effectiveness (Phase 2)Looking for participantsNCT06213636
What this trial is testing

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

Who this might be right for
Acute Lymphoblastic Leukemia, Adult B-CellAcute Lymphoblastic Leukemia, in RelapseNon-Hodgkin Lymphoma, B-cell+4 more
Essen Biotech 75
Early research (Phase 1)UnknownNCT05350852
What this trial is testing

Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL

Who this might be right for
B-ALL
Zhejiang University 16
Early research (Phase 1)Active Not RecruitingNCT03927261
What this trial is testing

PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Precigen, Inc 88
Testing effectiveness (Phase 2)Study completedNCT01784068
What this trial is testing

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

Who this might be right for
Chronic Myelogenous Leukemia
Novartis Pharmaceuticals 215
Testing effectiveness (Phase 2)UnknownNCT05079022
What this trial is testing

CtDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Who this might be right for
Adenocarcinoma of Lung
Peking University People's Hospital 50
Large-scale testing (Phase 3)UnknownNCT03027739
What this trial is testing

CART-19 Cells For MRD Positive CD19+ ALL

Who this might be right for
Acute Lymphoblastic Leukemia
Fujian Medical University 20
Early research (Phase 1)Study completedNCT01460498
What this trial is testing

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 3
Large-scale testing (Phase 3)Active Not RecruitingNCT04841811
What this trial is testing

MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)

Who this might be right for
Lung Cancer
Guangdong Association of Clinical Trials 192
Early research (Phase 1)Study completedNCT03919526
What this trial is testing

Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL

Who this might be right for
MRD-positiveAcute Lymphoblastic Leukemia
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 19
Testing effectiveness (Phase 2)WithdrawnNCT06570915
What this trial is testing

Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy

Who this might be right for
ALL, Adult
Institute of Hematology & Blood Diseases Hospital, China
Testing effectiveness (Phase 2)Looking for participantsNCT06985485
What this trial is testing

Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy

Who this might be right for
Acute Lymphoblastic LeukemiaImmunotherapyBlinatumomab+1 more
The First Affiliated Hospital of Soochow University 26
Not applicableLooking for participantsNCT06066905
What this trial is testing

Chidamide With AZA in MRD Positive AML After Transplant

Who this might be right for
AML, AdultMinimal Residual Disease
Guangdong Provincial People's Hospital 60
Testing effectiveness (Phase 2)WithdrawnNCT05846737
What this trial is testing

BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Testing effectiveness (Phase 2)Looking for participantsNCT07256210
What this trial is testing

Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic T-cell LeukemiaMixed Phenotype Acute Leukemia
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 15
Not applicableNot Yet RecruitingNCT06758726
What this trial is testing

Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML

Who this might be right for
AML
Institute of Hematology & Blood Diseases Hospital, China 20
Testing effectiveness (Phase 2)Study completedNCT03490344
What this trial is testing

Short Course Daratumumab in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 10
Next Page